image

Scientific Resources

Our Process of Scientific Discovery

Nurix’s dedicated scientists are changing the landscape of cancer treatment. Learn more about our leading-edge research and drug development technology by exploring our presentations, videos, and mechanisms of action.

Filter by
  • Year
    • 2024
    • 2023
    • 2022
    • 2021
    • 2020
  • Program
    • BRAF degrader
    • NX-2127
    • NX-5948
    • NX-1607
    • NX‑0479/GS‑6791
    • DeTIL-0255
  • Platform
    • Targeted Protein Degradation
    • Targeted Protein Elevation
    • Degrader Antibody Conjugate
    • DELigase
    • Other
Program: NX-5948
Efficacy-and-safety-of-the-Bruton’s-tyrosine-kinase-(BTK)-degrader-NX-5948-in-patients-with-relapsed-refractory-chronic-lymphocytic-leukemia--updated-results-from-an-ongoing-Phase-1a-b-study-thumb

Efficacy and safety of the Bruton’s tyrosine kinase (BTK) degrader NX-5948 in patients with relapsed/refractory chronic lymphocytic leukemia: updated results from an ongoing Phase 1a/b study

66TH American Society of Hematology (ASH) Annual Meeting
Monday, December 9, 2024
ACR Convergence 2024 Poster

NX-5948, a Clinical-Stage BTK Degrader, Achieves Deep Suppression of BCR, TLR, and FcR Signaling in Immune Cells and Demonstrates Efficacy in Preclinical Models of Arthritis and Other Inflammatory Diseases

ACR Convergence 2024
Saturday, November 16, 2024
Program: NX‑0479

IRAK4 Degrader GS-6791 Inhibits TLR and IL-1R-Driven Inflammatory Signaling, and Ameliorates Disease in a Preclinical Arthritis Model

ACR Convergence 2024
Friday, November 15, 2024
Program: BRAF-degrader

Clinical Activity of NX-5948: A First-in-Class BTK Degrader

7th Annual TPD & Induced Proximity Summit
Wednesday, October 30, 2024

An Orally Bioavailable, Brain Penetrant, Pan-Mutant BRAF Degrader for the Treatment of Primary and Inhibitor-Resistant Solid Tumors

7th Annual TPD & Induced Proximity Summit
Tuesday, October 29, 2024
NX-5948--BTK-Degrader-with-Activity-in-Lymphoid-Malignancies-thumb

NX-5948: BTK Degrader with Activity in Lymphoid Malignancies

12th International Workshop on Waldenstrom’s Macroglobulinemia
Saturday, October 19, 2024
Screening-DNA-Binding-Proteins-with-DNA-Encoded-Libraries-thumb

Screening DNA Binding Proteins with DNA Encoded Libraries

Discovery on Target
Thursday, October 3, 2024
The-Evolving-Chemical-Space-of-Bi-functional-Degraders-Targeting-the-CNS-thumb

The Evolving Chemical Space of Bi-functional Degraders Targeting the CNS

Discovery on Target
Tuesday, October 1, 2024
Program: NX-1607
Rational-Discovery-of-a-Small-Molecule-Intramolecular-Glue-Inhibitor-of-CBL-B-that-Enhances-T-cell-Function-thumb

Rational Discovery of a Small Molecule Intramolecular Glue Inhibitor of CBL-B that Enhances T-cell Function

Discovery on Target
Tuesday, October 1, 2024
Accelerating-Targeted-Protein-Degrader-Discovery-with-Automated-and-Integrated-Direct-To-Biology-Screening-thumb

Accelerating Targeted Protein Degrader Discovery with Automated and Integrated Direct-To-Biology Screening

Promega Protein Degradation Symposium
Tuesday, September 10, 2024
Targeted-Protein-Degraders-As-Next-Generation-Antibody-Payloads-thumb

Targeted Protein Degraders As Next Generation Antibody Payloads

ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit
Monday, September 9, 2024
Using-DEL-for-Targeted-Protein-Modulation-thumb

Using DEL for Targeted Protein Modulation

XXVIII EFMC International Symposium on Medicinal Chemistry (EFMC-ISMC)
Monday, September 2, 2024
A-Rapid-Matrix-Approach-for-the-Discovery-of-Potent-IRAK4-Targeted-Protein-Degraders thumbnail of presentation

A Rapid Matrix Approach for the Discovery of Potent IRAK4 Targeted Protein Degraders

Fall 2024 ACS Meeting
Wednesday, August 21, 2024

Latest Results from an Ongoing First-in-Human Phase 1a/b Study of NX-5948, a Selective Bruton’s Tyrosine Kinase (BTK) Degrader, in Patients with Relapsed/Refractory CLL and Other B-cell Malignancies

European Hematology Association Congress (EHA2024)
Sunday, June 16, 2024
Automated-Method-Development-for-High-Throughput-Purification-at-Nurix-Therapeutics thumb

Automated Method Development for High Throughput Purification at Nurix Therapeutics 

36th International Symposium on Preparative and Process Chromatography
Tuesday, May 28, 2024
Initial-finding-from-a-first-in-human-Phase-1a-b-trial-of-NX-5948-a-selective-BTK-degrader--thumb

Initial finding from a first-in-human Phase 1a/b trial of NX-5948, a selective BTK degrader

British Society of Haematology Annual Meeting (BSH)
Sunday, April 28, 2024
Initial-Findings-From-a-First-in-Human-Phase-1a-b-Trial-of-NX-5948,-a-Selective-Bruton’s-Tyrosine-Kinase-Degrader,-in-Patients-with--Relapsed-Refractory-B-Cell-Malignancies-thumb

Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies

21st Annual International Ultmann Chicago Lymphoma Symposium (IUCLS)
Friday, April 19, 2024
NX-5948,-a-brain-penetrant-BTK-degrader-with-clinical-activity-in-B-cell-malignancies-including-CNS-lymphoma-thumb

NX-5948, a brain-penetrant BTK degrader with clinical activity in B-cell malignancies including CNS lymphoma

American Association for Cancer Research (AACR) 2024 Annual Meeting
Tuesday, April 9, 2024
Targeting-Degraders-to-the-CNS-for-the-Treatment-of-Cancer-thumb

Targeting Degraders to the CNS for the Treatment of Cancer

American Association for Cancer Research (AACR) 2024 Annual Meeting
Friday, April 5, 2024
Initial-Findings-From-a-First-in-Human-Phase-1a-b-Trial-of-NX-5948,-a-Selective-Bruton’s-Tyrosine-Kinase-Degrader,-in-Patients-with-Relapsed-Refractory-B-Cell-Malignancies-thumb

Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies

DAVA Oncology Whistler Global Summit on Hematologic Oncology in Whistler, BC, Canada
Wednesday, April 3, 2024
Approaches-for-DNA-Encoded-Library-Screening-of-Transcription-Factors--thumb

Approaches for DNA-Encoded Library Screening of Transcription Factors

Drug Discovery Chemistry (DDC)
Tuesday, April 2, 2024
NX-1607--a-First-In-Class-Inhibitor-of-Casitas-B-lineage-Lymphoma-B-(CBL-B)-for-Immuno-Oncology-thumb

NX-1607: a First-In-Class Inhibitor of Casitas B-lineage Lymphoma B (CBL-B) for Immuno-Oncology

Drug Discovery Chemistry (DDC)
Tuesday, April 2, 2024
Program: NX-2127
TPD-EU-2024-thumb

Findings From the First-in-Human Phase 1 Trials of NX-2127 and NX-5948, Bruton’s Tyrosine Kinase (BTK) Degraders, in Patients with Relapsed/Refractory B-Cell Malignancies 

4th Targeted Protein Degradation (TPD) Summit Europe
Thursday, March 21, 2024
ACS-2024-NX-1607-thumb

NX-1607: a First-In-Class Inhibitor of Casitas B-lineage Lymphoma B (CBL-B) for Immuno-Oncology 

American Chemical Society (ACS) Spring 2024
Wednesday, March 20, 2024

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies

28th Annual International Congress on Hematologic Malignancies
Thursday, February 29, 2024
Relapsed-Refractory-B-Cell-Malignancies-thumb

Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies

28th Annual International Congress on Hematologic Malignancies
Thursday, February 29, 2024
Role-of-Ternary-Complex-Formation-and-Ubiquitylation-Assays-in-Early-Protein-Degrader-Discovery-thumb

Role of Ternary Complex Formation and Ubiquitylation Assays in Early Protein Degrader Discovery

TPD Assays and Screening
Friday, December 15, 2023
ASH-Event-Presentation-thumbnail

ASH Event Presentation 2023

American Society of Hematology (ASH) 2023
Tuesday, December 12, 2023
Initial-Findings-From-a-First-in-Human-Phase-1a-b-Trial-of-NX-5948-a-Selective-Brutons-Tyrosine-Kinase-Degrader-in-Patients-with-Relapsed-Refractory-B-Cell-Malignancies-thumb

Initial Findings From a First-in-Human Phase 1a/b Trial of NX-5948, a Selective Bruton’s Tyrosine Kinase Degrader, in Patients with Relapsed/Refractory B-Cell Malignancies 

American Society of Hematology (ASH) 2023
Monday, December 11, 2023
A-First-in-Human-Phase-1-Tthumb

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Bruton’s Tyrosine Kinase Dual-Targeted Protein Degrader with Immunomodulatory Activity, in Patients with Relapsed/Refractory B-Cell Malignancies 

American Society of Hematology (ASH) 2023
Monday, December 11, 2023
A-First-in-Human-Phase-1-Trial-of-NX-1607-thumb

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies Including Diffuse Large B-Cell Lymphoma

American Society of Hematology (ASH) 2023
Monday, December 11, 2023

NX-1607, a small molecule inhibitor of CBL-B, enhances anti-PD-1-mediated tumor growth inhibition by reshaping intratumoral innate and adaptive immune responses

SITC 2023
Wednesday, November 1, 2023
6th Annual Targeted Protein Degradation Summit thumb

Overcoming Acquired Inhibitor Resistance & Addressing Novel Scaffolding Functions of BTK in the Clinic 

6th Annual Targeted Protein Degradation Summit
Tuesday, October 31, 2023
NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders thumb

NX-5948 and NX-2127 potently degrade a broad array of clinically-relevant BTK mutants that display resistance to inhibitors and other BTK degraders

International Workshop on CLL (iwCLL)
Friday, October 6, 2023
NX-2127: A Degrader of BTK and IKZF1/3 thumb

NX-2127: A Degrader of BTK and IKZF1/3

Discovery on Target: Targeting Transcription Factors
Thursday, September 28, 2023
Targeting a Novel E3 Ligase with a Small Molecule Inhibitor thumb

Targeting a Novel E3 Ligase with a Small Molecule Inhibitor

Discovery on Target
Wednesday, September 27, 2023
Targeted Protein Degradation of BTK Overcomes Clinically-Relevant Resistance Mutations and Its Oncogenic Scaffolding Functions thumb

Targeted Protein Degradation of BTK Overcomes Clinically-Relevant Resistance Mutations and Its Oncogenic Scaffolding Functions

Discovery on Target – Small Molecules for Cancer Targets
Tuesday, September 26, 2023
NX-1607-a-small-molecule-inhibitor-of-CBL-B,-is-efficacious-as-a-single-agent-and-in-combination-with-Rituximab-in-preclinical-mouse-models-of-lymphoma-thumb

NX-1607, a small molecule inhibitor of CBL-B, is efficacious as a single agent and in combination with Rituximab in preclinical mouse models of lymphoma

International Cancer Immunotherapy Conference (CICON)
Monday, September 25, 2023
Protein Degradation & Targeting Undruggables Congress Europe

Targeted Protein Degraders for the Treatment of Hematologic Malignancies: Addressing the Mutational Resistance of BTK in the Clinic

Protein Degradation & Targeting Undruggables Congress Europe
Wednesday, September 20, 2023
First-Disclosure-of-NX-5948,-an-Oral-Targeted-Degrader-of-Bruton's-Tyrosine-Kinase-(BTK)-for-the-Treatment-of-B-cell-Malignancies-thbuymb

First Disclosure of NX-5948, an Oral Targeted Degrader of Bruton’s Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies

American Chemical Society (ACS) Conference
Wednesday, August 16, 2023

Targeted Protein Degradation for Treatment of Hematologic Malignancies Addressing Both the Enzymatic and Scaffolding Functions of BTK Using NX-5948 and NX-2127 in the Clinic

2nd Targeted Protein Degradation in Japan
Wednesday, July 26, 2023

Proof of concept of NX-2127, a first-in-class Bruton’s Tyrosine Kinase (BTK) dual-targeted protein degrader with immunomodulatory activity, in patients with DLBCL

17th International Conference of malignant Lymphoma (ICML) Meeting
Wednesday, June 14, 2023

BTK Degradation as a Novel Therapeutic Strategy in Relapsed CNS Lymphoma: Preclinical Proof of Concept Studies in Intracranial Patient-Derived Model

17th International Conference of malignant Lymphoma (ICML) Meeting
Wednesday, June 14, 2023

Drug-resistance mutations in BTK occur in distinct enzymatic classes and are overcome by BTK degradation

17th International Conference of malignant Lymphoma (ICML) Meeting
Wednesday, June 14, 2023

Robust Bruton’s tyrosine kinase (BTK) degradation with NX-5948, an oral BTK degrader, in a first-in-human phase 1a trial in patients with relapsed/refractory B cell malignancies

17th International Conference of malignant Lymphoma (ICML) Meeting
Wednesday, June 14, 2023

Deploying Affinity Selection Mass Spectrometry (ASMS) for Rapid and Flexible Hit Confirmation of DNA-Encoded Library (DEL) Screening in Targeted Protein Modulation (TPM)

3rd Annual Edelris ASMS Symposium
Wednesday, May 31, 2023

Discovery and development of targeted protein modulators for the treatment of hematologic malignancies and solid tumors 

American Society for Pharmacology and Experimental Therapeutics
Friday, May 19, 2023

Exploring Success with Targeting a Novel E3 Ligase with a Small Molecule Inhibitor

3rd Annual Ligase Targeting Drug Development
Tuesday, April 25, 2023

First Disclosure of NX-2127, an oral targeted degrader of Bruton’s tyrosine kinase (BTK) with concurrent immunomodulatory activity for the treatment of B-cell malignancies

American Association for Cancer Research (AACR) 2023 Annual Meeting
Monday, April 17, 2023

NX-5948 promotes selective, sub-nanomolar degradation of inhibitor-resistant BTK mutants

American Association for Cancer Research (AACR) 2023 Annual Meeting
Monday, April 17, 2023
Ligase-Inhibition-Workshop-thumb

Ligase Inhibition Workshop

3rd Annual Ligase Targeting Drug Development
Tuesday, April 11, 2023
Developing-Predictive-ML-Models-to-Inform-TPD-Lead-Optimization-thumb

Developing Predictive ML Models to Inform TPD Lead Optimization

TPD Europe
Monday, April 3, 2023
First-Targeted-Protein-Degradation-for-Hematological-Malignancies-thumb

First Targeted Protein Degradation for Hematological Malignancies

3rd Annual Targeted Protein Degradation Europe
Monday, April 3, 2023
Targeted-Protein-Degradation-of-BTK-for-Hematological-Malignancies-and-Autoimmune-Disease--Preclinical-and-Initial-Phase-1a-PK-PD-Data-for-NX-5948-thumb

Targeted Protein Degradation of BTK for Hematological Malignancies and Autoimmune Disease: Preclinical and Initial Phase 1a PK/PD Data for NX-5948

4th Protein Degradation & Targeting Undruggables Congress
Wednesday, March 15, 2023
Utilizing-DEL-as-a-Primary-Discovery-Engine-for-Targeted-Protein-Modulation-thumb

Utilizing DEL as a Primary Discovery Engine for Targeted Protein Modulation

UCI Pharm Sci Spring Seminar Series
Wednesday, February 8, 2023
Discovery-and-Optimization-of-CBL-B-Inhibitors-Thumb

Discovery and Optimization of CBL-B Inhibitors

Dana Farber TPD Webinar
Thursday, February 2, 2023

ASH Event Presentation

American Society of Hematology (ASH)
Monday, December 12, 2022
Molecular Property Prediction Using Machine Learning

Molecular Property Prediction Using Machine Learning

TPD Assay Summit
Tuesday, December 6, 2022
Chemistry @Nurix: Protein Modulation for Drug Discovery

Chemistry @Nurix: Protein Modulation for Drug Discovery

Bay Area Chemistry Symposium
Thursday, November 10, 2022
NX-1607,-a-Small-Molecule-Inhibitor-of-the-CBL-B-E3-Ubiquitin-Ligase,-Promotes-T-and-NK-Cell-Activation-and-Enhances-NK-mediated-ADCC-in-a-Mouse-Lymphoma-Tumor-Model-thumb

NX-1607, a Small Molecule Inhibitor of the CBL-B E3 Ubiquitin Ligase, Promotes T and NK Cell Activation and Enhances NK-mediated ADCC in a Mouse Lymphoma Tumor Model 

SITC 37th Annual Meeting
Thursday, November 10, 2022
Program: DeTIL-0255
The-CBL-B-Inhibitor,-NX-0255,-Improves-Human-Drug-Enhanced-Tumor-Infiltrating-Lymphocyte-(DeTIL-0255)-Expansion-and-T-cell-Function-in-Full-scale-Runs-thumb

The CBL-B Inhibitor, NX-0255, Improves Human Drug Enhanced Tumor Infiltrating Lymphocyte (DeTIL-0255) Expansion and T-cell Function in Full-scale Runs 

SITC 37th Annual Meeting
Thursday, November 10, 2022
DeTIL 0255 Ovarian SITC 2022 poster 22 Oct 2022

Universal Expansion of CBL-B–inhibited Tumor-Infiltrating Lymphocytes, DeTIL-0255, from Women with Ovarian Cancer: Process Validation 

SITC 37th Annual Meeting
Thursday, November 10, 2022
A-Phase-1-Adoptive-Cell-Therapy-Using-Drug-Enhanced,-Tumor-Infiltrating-Lymphocytes,-DeTIL-0255,-in-Adults-With-Advanced-Malignancies-thumb

A Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies 

SITC 37th Annual Meeting
Thursday, November 10, 2022
Initial-Clinical-Characterization-of-Novel-Proximal-Biomarkers-for-NX-1607,-a-First-in-Class-Oral-CBL-B-Inhibitor,-in-Patients-with-Advanced-Malignancies-thumb

Initial Clinical Characterization of Novel Proximal Biomarkers for NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Malignancies 

SITC 37th Annual Meeting
Thursday, November 10, 2022
A-Novel-Small-Molecule-Inhibitor-of-CBL-B-Shows-Potent-Antitumor-Activity-in-Combination-with-Pmel-1-Adoptive-Cell-Transfer-in-an-Aggressive-Mouse-Melanoma-Model-thumb

A Novel Small Molecule Inhibitor of CBL-B Shows Potent Antitumor Activity in Combination with Pmel-1 Adoptive Cell Transfer in an Aggressive Mouse Melanoma Model 

SITC 37th Annual Meeting
Thursday, November 10, 2022
5th Annual TPD Summit

Discovery of Orally Active, Brain-Penetrant, Targeted Protein Degraders

5th Annual Targeted Protein Degradation (TPD) Summit
Wednesday, October 26, 2022
Utilizing DEL as a Primary Discovery Engine for Targeted Protein Degradation

Utilizing DEL as a Primary Discovery Engine for Targeted Protein Degradation

5th Annual Targeted Protein Degradation (TPD) Summit
Wednesday, October 26, 2022
The First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic

The First BTK Degraders in Hematologic Malignancies: The Latest from the Clinic

5th Annual Targeted Protein Degradation (TPD) Summit
Wednesday, October 26, 2022
Combining-TIL-with-Small-Molecule-Inhibitors-to-Enhance-T-Cell-Expansion-&-Phenotypes-thumb

Combining TIL with Small Molecule Inhibitors to Enhance T-Cell Expansion & Phenotypes

4th TIL Therapies Summit
Tuesday, October 25, 2022
Discovery-and-Optimization-of-CBL-B-Inhibitors-thumb

Discovery and Optimization of CBL-B Inhibitors 

Discovery On Target
Tuesday, October 18, 2022
NX-1607,-an-inhibitor-of-the-CBL-B-E3-ubiquitin-ligase,-promotes-favorable-local-and-systemic-changes-in-infiltrating-immune-cells-in-multiple-mouse-tumor-models-thumb

NX-1607, an inhibitor of the CBL-B E3 ubiquitin ligase, promotes favorable local and systemic changes in infiltrating immune cells in multiple mouse tumor models 

CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference
Friday, September 30, 2022
Inhibitors-of-the-E3-Ubiquitin-Ligase-CBL-B-Promote-Potent-T-and-NK-Cell-Mediated-Anti-Tumor-Response-thumb

Inhibitors of the E3 Ubiquitin Ligase CBL-B Promote Potent T and NK Cell Mediated Anti-Tumor Response

Non-Small Cell Lung Cancer Drug Development Summit
Wednesday, September 21, 2022
First-Targeted-Protein-Degrader-for-Hematologic-Malignancies-thumb

First Targeted Protein Degrader for Hematologic Malignancies

Promega TPD Symposium
Tuesday, September 20, 2022
Discovery-and-Optimization-of-CBL-B-Inhibitors-Thumb

Discovery and Optimization of CBL-B Inhibitors

American Chemical Society (ACS) Fall Meeting
Tuesday, August 23, 2022
Exploring-NX-5948--A-CNS-Penetrant-Selective-Degrader-of-BTK-that-Significantly-Reduces-Inflammation-in-Mouse-Models-of-Autoimmune-Disease-thumb

Exploring NX-5948: A CNS Penetrant Selective Degrader of BTK that Significantly Reduces Inflammation in Mouse Models of Autoimmune Disease 

3rd Annual B & T Cell-Mediated Autoimmune Disease Drug Development Summit
Wednesday, July 27, 2022
A-First-in-Human-Phase-1-Trial-of-NX-2127,-a-First-in-Class-Oral-BTK-Degrader-With-Immunomodulatory-Activity,-in-Patients-With-Relapsed-and-Refractory-B-Cell-Malignancies-thumb

A First-in-Human Phase 1 Trial of NX-5948, an Oral BTK Degrader, in Patients with Relapsed and Refractory B-cell Malignancies

European Hermatology Association (EHA) 2022 Hybrid Congress
Thursday, June 9, 2022
European-Hermatology-Association-EHA-2022-Hybrid-Congress-thumb

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies

European Hermatology Association (EHA) 2022 Hybrid Congress
Thursday, June 9, 2022
The-CBL-B-Inhibitor,-NX-0255,-Enhances-Human-Drug-Enhanced-Tumor-Infiltrating-Lymphocyte-(DeTIL)-Expansion-and-T-Cell-Function-in-Full-Scale-Runs-thumb

The CBL-B Inhibitor, NX-0255, Enhances Human Drug-Enhanced Tumor-Infiltrating Lymphocyte (DeTIL) Expansion and T Cell Function in Full-Scale Runs

24th Annual Translational Research Cancer Centers Consortium (TRCCC) Meeting
Monday, June 6, 2022
A-Phase-1-Adoptive-Cell-Therapy-Using-Drug-Enhanced,-Tumor-Infiltrating-Lymphocytes,-DeTIL-0255,-in-Adults-With-Advanced-Malignancies-thumb

A Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies

24th Annual Translational Research Cancer Centers Consortium (TRCCC) Meeting
Monday, June 6, 2022
Modeling-Limit-of-Detection-for-Dominant-T-Cell-Receptor-Clones-Reveals-Comparable-Measures-Across-RNA-and-DNA-Based-Sequencing-thumb

Modeling Limit of Detection for Dominant T Cell Receptor Clones Reveals Comparable Measures Across RNA and DNA Based Sequencing

24th Annual Translational Research Cancer Centers Consortium (TRCCC) Meeting
Monday, June 6, 2022
A-Phase-1-Adoptive-Cell-Therapy-Using-Drug-Enhanced,-Tumor-Infiltrating-Lymphocytes,-DeTIL-0255,-in-Adults-With-Advanced-Malignancies-thumb

A Phase 1 Adoptive Cell Therapy Using Drug-Enhanced, Tumor-Infiltrating Lymphocytes, DeTIL-0255, in Adults With Advanced Malignancies

American Society of Clinical Oncology (ASCO) Annual Meeting
Friday, June 3, 2022
A-First-in-Human-Phase-1-Trial-of-NX-2127,-a-First-in-Class-Oral-BTK-Degrader-With-Immunomodulatory-Activity,-in-Patients-With-Relapsed-and-Refractory-B-Cell-Malignancies-thumb

A First-in-Human Phase 1 Trial of NX-2127, a First-in-Class Oral BTK Degrader With Immunomodulatory Activity, in Patients With Relapsed and Refractory B-Cell Malignancies

American Society of Clinical Oncology (ASCO) Annual Meeting
Friday, June 3, 2022
A-First-in-Human-Phase-1-Trial-of-NX-1607,-a-First-in-Class-Oral-CBL-B-Inhibitor,-in-Patients-with-Advanced-Solid-Tumors-thumb

A First-in-Human Phase 1 Trial of NX-1607, a First-in-Class Oral CBL-B Inhibitor, in Patients with Advanced Solid Tumors

American Society of Clinical Oncology (ASCO) Annual Meeting
Friday, June 3, 2022

R&D Day

New York, NY
Thursday, May 26, 2022
Application-of-DNA-Encoded-Libraries-to-Discover-Small-Molecules-for-E3-Ligase-Modulation-Thumb

Application of DNA-Encoded Libraries to Discover Small Molecules for E3 Ligase Modulation

2nd Annual Ligase Targeting Drug Development
Thursday, April 28, 2022
Applying-DEL-Discovery-to-Protein-Modulation-Thumb

Applying DEL Discovery to Protein Modulation

17th Annual Drug Discovery Chemistry
Tuesday, April 19, 2022
Inhibitors-of-the-E3-Ubiquitin-Ligase-CBL-B-Promote-Potent-T-and-NK-Cell-Mediated-Anti-Tumor-Response-Thumb

Inhibitors of the E3 Ubiquitin Ligase CBL-B Promote Potent T and NK Cell Mediated Anti-Tumor Response

17th Annual Drug Discovery Chemistry
Tuesday, April 19, 2022
Concurrent-degradation-of-BTK-and-IMiD-neosubstrates-by-NX-2127-enhances-multiple-mechanisms-of-tumor-killing-Thumb

Concurrent degradation of BTK and IMiD neosubstrates by NX-2127 enhances multiple mechanisms of tumor killing

American Association for Cancer Research (AACR) 2022 Annual Meeting
Tuesday, April 12, 2022
Ex-vivo-inhibition-of-CBL-B-with-a-novel-small-molecule-inhibitor-NX-0255-enhances-persistence-and-anti-tumor-activity-of-adoptively-transferred-CD8-T-cells-in-mouse-tumor-models-Thumb

Ex-vivo inhibition of CBL-B with a novel small molecule inhibitor, NX-0255, enhances persistence and anti-tumor activity of adoptively transferred CD8+ T cells in mouse tumor models

American Association for Cancer Research (AACR) 2022 Annual Meeting
Friday, April 8, 2022
NX‑5948-a-Selective-Degrader-of-BTK-With-Activity-in-Preclinical-Models-of-Hematologic-and-Brain-Malignancies-Thumb

NX‑5948, a Selective Degrader of BTK With Activity in Preclinical Models of Hematologic and Brain Malignancies

63rd American Society of Hematology (ASH) Annual Meeting
Sunday, December 12, 2021
NX‑0255-a-Small‑Molecule-CBL‑B-Inhibitor-Expands-and-Enhances-Tumor‑Infiltrating-Thumb

NX‑0255, a Small‑Molecule CBL‑B Inhibitor, Expands and Enhances Tumor‑Infiltrating
Lymphocytes for Use in Adoptive Cancer Immunotherapy

Society for Immunotherapy of Cancer 36th Annual Meeting
Friday, November 12, 2021
First-Demonstration-of-Targeted-Protein-Degradation-of-BTK-in-Hematologic-MalignanciesInitial-NX-2127-Phase-1a-PK-PD-Data-Thumb

First Demonstration of Targeted Protein Degradation of BTK in Hematologic Malignancies: Initial NX-2127 Phase 1a PK/PD Data

4th Annual Targeted Protein Degradation Summit
Wednesday, October 27, 2021
Nurix-Therapeutics-Presentation-Thumb

Nurix Therapeutics Presentation

European Protein Degradation Congress Presentation
Wednesday, September 22, 2021
NX-5948-a-Selective-Degrader-of-BTK-Significantly-Reduces-Inflammation-in-a-Model-of-Autoimmune-Disease-Thumb

NX-5948, a Selective Degrader of BTK, Significantly Reduces Inflammation in a Model of Autoimmune Disease

European Alliance of Associations for Rheumatology (EULAR) 2021 Virtual Congress
Wednesday, June 2, 2021
Small-molecule-inhibition-of-the-ubiquitin-ligase-CBL-B-with-NX-1607-results-in-potent-T-and-NK-cell-mediated-anti-tumor-response-Thumb

Small molecule inhibition of the ubiquitin ligase CBL-B with NX-1607 results in potent T and NK cell mediated anti-tumor response

American Association for Cancer Research (AACR) 2021 Annual Meeting
Saturday, April 10, 2021
NX-2127-a-Degrader-of-BTK-and-IMiD-Neosubstrates-for-the-Treatment-of-B-Cell-Malignancies-Thumb

NX-2127, a Degrader of BTK and IMiD Neosubstrates, for the Treatment of B-Cell Malignancies

62nd American Society of Hematology (ASH) Annual Meeting
Monday, December 7, 2020
Targeted-Protein-ModulationHarnessing-or-Inhibiting-E3-Ligases-to-Decrease-or-Increase-Protein-Levels-Thumb

Targeted Protein Modulation: Harnessing or Inhibiting E3 Ligases to Decrease or Increase Protein Levels

3rd Targeted Protein Degradation Summit 2020
Wednesday, October 14, 2020

Nurix: Targeted Protein Degradation

Nurix: DEL Technology

MENU '